T2 Biosystems Announces Exclusive U.S. Agreement With Cardinal Health to Sell Its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
t2 biosystems宣佈與卡地納健康達成獨家美國協議,銷售其獲FDA批准的直接血液檢測產品,用於快速檢測導致敗血症的病原體
T2 Biosystems Announces Exclusive U.S. Agreement With Cardinal Health to Sell Its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
t2 biosystems宣佈與卡地納健康達成獨家美國協議,銷售其獲FDA批准的直接血液檢測產品,用於快速檢測導致敗血症的病原體
譯文內容由第三人軟體翻譯。